Monoclonal Antibodies (mAbs) Market 2027 By Source, Production, Indication, End User and Geography | The Insight Partners

Monoclonal Antibodies (mAbs) Market to 2027 - Global Analysis and Forecasts By Source (Murine, Chimeric, Humanized, Human); Production (In Vivo, In Vitro); Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others); End User (Hospitals, Research Institutes, Others) and Geography

Report Code: TIPRE00004911 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming
MARKET INTRODUCTION
The antibodies are proteins produced by body's immune system in response to antigens in the form of bacteria, viruses, parasites and others that are identified as foreign. Monoclonal antibodies are protein produced by immune system that targets a specific antigen in body. Monoclonal antibodies are used in immunotherapy such as in diagnosis and treatment of cancer and other diseases. However, some of the monoclonal antibodies has side effects such as vomiting, rash, weakness, fever, insomnia and others.

MARKET DYNAMICS
The monoclonal antibodies (mAbs) market are expected to grow in upcoming years due to increase in prevalence of cancer and other chronic diseases, awareness among the patients and physicians about latest therapies, increase in demand for personalized medicine which is customized treatment offer to the individual, growth in development of therapeutic antibodies and others. On the other hand increasing R&D activities in genomics and new strategies for delivery of monoclonal antibodies are likely to offer growth opportunities in monoclonal antibodies (mAbs) market.

MARKET SCOPE
The "Global Monoclonal Antibodies (mAbs) Market for Medical Implants Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of monoclonal antibodies (mAbs) market with detailed market segmentation by source, production, indication, end user and geography. The global monoclonal antibodies (mAbs) market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading monoclonal antibodies (mAbs) market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global monoclonal antibodies (mAbs) market is segmented on the basis of source, production, indication and end user. Based on source, the market is segmented as murine, chimeric, humanized, and human. On the basis of production, the global monoclonal antibodies (mAbs) market is segmented into in-vivo and in-vitro. Based on indication, the market is segmented as cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases and others. Based on end users, the market is segmented as hospitals, research institutes and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global monoclonal antibodies (mAbs) market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The monoclonal antibodies (mAbs) market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting monoclonal antibodies (mAbs) market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the monoclonal antibodies (mAbs) market in these regions.

MARKET PLAYERS
The reports cover key developments in the monoclonal antibodies (mAbs) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from monoclonal antibodies (mAbs) market are anticipated to lucrative growth opportunities in the future with the rising demand for monoclonal antibodies (mAbs) in the global market. Below mentioned is the list of few companies engaged in the monoclonal antibodies (mAbs) market.

The report also includes the profiles of key monoclonal antibodies (mAbs) market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Amgen, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Abbott
  • AstraZeneca
  • Eli Lilly and Company
  • Bayer AG
  • Bristol-Myers Squibb Company.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Monoclonal Antibodies (mAbs) Market - By Source
1.3.2 Monoclonal Antibodies (mAbs) Market - By Production
1.3.3 Monoclonal Antibodies (mAbs) Market - By Indication
1.3.4 Monoclonal Antibodies (mAbs) Market - By End User
1.3.5 Monoclonal Antibodies (mAbs) Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MONOCLONAL ANTIBODIES (MABS) MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MONOCLONAL ANTIBODIES (MABS) MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. MONOCLONAL ANTIBODIES (MABS) MARKET - GLOBAL MARKET ANALYSIS
6.1. MONOCLONAL ANTIBODIES (MABS) - GLOBAL MARKET OVERVIEW
6.2. MONOCLONAL ANTIBODIES (MABS) - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. MONOCLONAL ANTIBODIES (MABS) MARKET - REVENUE AND FORECASTS TO 2027 - SOURCE
7.1. OVERVIEW
7.2. SOURCE MARKET FORECASTS AND ANALYSIS
7.3. MURINE
7.3.1. Overview
7.3.2. Murine Market Forecast and Analysis
7.4. CHIMERIC
7.4.1. Overview
7.4.2. Chimeric Market Forecast and Analysis
7.5. HUMANIZED
7.5.1. Overview
7.5.2. Humanized Market Forecast and Analysis
7.6. HUMAN
7.6.1. Overview
7.6.2. Human Market Forecast and Analysis
8. MONOCLONAL ANTIBODIES (MABS) MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCTION
8.1. OVERVIEW
8.2. PRODUCTION MARKET FORECASTS AND ANALYSIS
8.3. IN VIVO
8.3.1. Overview
8.3.2. In Vivo Market Forecast and Analysis
8.4. IN VITRO
8.4.1. Overview
8.4.2. In Vitro Market Forecast and Analysis
9. MONOCLONAL ANTIBODIES (MABS) MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
9.1. OVERVIEW
9.2. INDICATION MARKET FORECASTS AND ANALYSIS
9.3. CANCER
9.3.1. Overview
9.3.2. Cancer Market Forecast and Analysis
9.4. AUTOIMMUNE DISEASES
9.4.1. Overview
9.4.2. Autoimmune Diseases Market Forecast and Analysis
9.5. INFLAMMATORY DISEASES
9.5.1. Overview
9.5.2. Inflammatory Diseases Market Forecast and Analysis
9.6. INFECTIOUS DISEASES
9.6.1. Overview
9.6.2. Infectious Diseases Market Forecast and Analysis
9.7. MICROBIAL DISEASES
9.7.1. Overview
9.7.2. Microbial Diseases Market Forecast and Analysis
9.8. OTHERS
9.8.1. Overview
9.8.2. Others Market Forecast and Analysis
10. MONOCLONAL ANTIBODIES (MABS) MARKET - REVENUE AND FORECASTS TO 2027 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS
10.3.1. Overview
10.3.2. Hospitals Market Forecast and Analysis
10.4. RESEARCH INSTITUTES
10.4.1. Overview
10.4.2. Research Institutes Market Forecast and Analysis
10.5. OTHERS
10.5.1. Overview
10.5.2. Others Market Forecast and Analysis
11. MONOCLONAL ANTIBODIES (MABS) MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Monoclonal Antibodies (mAbs) Market Overview
11.1.2 North America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis
11.1.3 North America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Source
11.1.4 North America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Production
11.1.5 North America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Indication
11.1.6 North America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By End User
11.1.7 North America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Countries
11.1.7.1 United States Monoclonal Antibodies (mAbs) Market
11.1.7.1.1 United States Monoclonal Antibodies (mAbs) Market by Source
11.1.7.1.2 United States Monoclonal Antibodies (mAbs) Market by Production
11.1.7.1.3 United States Monoclonal Antibodies (mAbs) Market by Indication
11.1.7.1.4 United States Monoclonal Antibodies (mAbs) Market by End User
11.1.7.2 Canada Monoclonal Antibodies (mAbs) Market
11.1.7.2.1 Canada Monoclonal Antibodies (mAbs) Market by Source
11.1.7.2.2 Canada Monoclonal Antibodies (mAbs) Market by Production
11.1.7.2.3 Canada Monoclonal Antibodies (mAbs) Market by Indication
11.1.7.2.4 Canada Monoclonal Antibodies (mAbs) Market by End User
11.1.7.3 Mexico Monoclonal Antibodies (mAbs) Market
11.1.7.3.1 Mexico Monoclonal Antibodies (mAbs) Market by Source
11.1.7.3.2 Mexico Monoclonal Antibodies (mAbs) Market by Production
11.1.7.3.3 Mexico Monoclonal Antibodies (mAbs) Market by Indication
11.1.7.3.4 Mexico Monoclonal Antibodies (mAbs) Market by End User
11.2. EUROPE
11.2.1 Europe Monoclonal Antibodies (mAbs) Market Overview
11.2.2 Europe Monoclonal Antibodies (mAbs) Market Forecasts and Analysis
11.2.3 Europe Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Source
11.2.4 Europe Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Production
11.2.5 Europe Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Indication
11.2.6 Europe Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By End User
11.2.7 Europe Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Monoclonal Antibodies (mAbs) Market
11.2.7.1.1 Germany Monoclonal Antibodies (mAbs) Market by Source
11.2.7.1.2 Germany Monoclonal Antibodies (mAbs) Market by Production
11.2.7.1.3 Germany Monoclonal Antibodies (mAbs) Market by Indication
11.2.7.1.4 Germany Monoclonal Antibodies (mAbs) Market by End User
11.2.7.2 France Monoclonal Antibodies (mAbs) Market
11.2.7.2.1 France Monoclonal Antibodies (mAbs) Market by Source
11.2.7.2.2 France Monoclonal Antibodies (mAbs) Market by Production
11.2.7.2.3 France Monoclonal Antibodies (mAbs) Market by Indication
11.2.7.2.4 France Monoclonal Antibodies (mAbs) Market by End User
11.2.7.3 Italy Monoclonal Antibodies (mAbs) Market
11.2.7.3.1 Italy Monoclonal Antibodies (mAbs) Market by Source
11.2.7.3.2 Italy Monoclonal Antibodies (mAbs) Market by Production
11.2.7.3.3 Italy Monoclonal Antibodies (mAbs) Market by Indication
11.2.7.3.4 Italy Monoclonal Antibodies (mAbs) Market by End User
11.2.7.4 Spain Monoclonal Antibodies (mAbs) Market
11.2.7.4.1 Spain Monoclonal Antibodies (mAbs) Market by Source
11.2.7.4.2 Spain Monoclonal Antibodies (mAbs) Market by Production
11.2.7.4.3 Spain Monoclonal Antibodies (mAbs) Market by Indication
11.2.7.4.4 Spain Monoclonal Antibodies (mAbs) Market by End User
11.2.7.5 United Kingdom Monoclonal Antibodies (mAbs) Market
11.2.7.5.1 United Kingdom Monoclonal Antibodies (mAbs) Market by Source
11.2.7.5.2 United Kingdom Monoclonal Antibodies (mAbs) Market by Production
11.2.7.5.3 United Kingdom Monoclonal Antibodies (mAbs) Market by Indication
11.2.7.5.4 United Kingdom Monoclonal Antibodies (mAbs) Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Monoclonal Antibodies (mAbs) Market Overview
11.3.2 Asia-Pacific Monoclonal Antibodies (mAbs) Market Forecasts and Analysis
11.3.3 Asia-Pacific Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Source
11.3.4 Asia-Pacific Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Production
11.3.5 Asia-Pacific Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Indication
11.3.6 Asia-Pacific Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Monoclonal Antibodies (mAbs) Market
11.3.7.1.1 Australia Monoclonal Antibodies (mAbs) Market by Source
11.3.7.1.2 Australia Monoclonal Antibodies (mAbs) Market by Production
11.3.7.1.3 Australia Monoclonal Antibodies (mAbs) Market by Indication
11.3.7.1.4 Australia Monoclonal Antibodies (mAbs) Market by End User
11.3.7.2 China Monoclonal Antibodies (mAbs) Market
11.3.7.2.1 China Monoclonal Antibodies (mAbs) Market by Source
11.3.7.2.2 China Monoclonal Antibodies (mAbs) Market by Production
11.3.7.2.3 China Monoclonal Antibodies (mAbs) Market by Indication
11.3.7.2.4 China Monoclonal Antibodies (mAbs) Market by End User
11.3.7.3 India Monoclonal Antibodies (mAbs) Market
11.3.7.3.1 India Monoclonal Antibodies (mAbs) Market by Source
11.3.7.3.2 India Monoclonal Antibodies (mAbs) Market by Production
11.3.7.3.3 India Monoclonal Antibodies (mAbs) Market by Indication
11.3.7.3.4 India Monoclonal Antibodies (mAbs) Market by End User
11.3.7.4 Japan Monoclonal Antibodies (mAbs) Market
11.3.7.4.1 Japan Monoclonal Antibodies (mAbs) Market by Source
11.3.7.4.2 Japan Monoclonal Antibodies (mAbs) Market by Production
11.3.7.4.3 Japan Monoclonal Antibodies (mAbs) Market by Indication
11.3.7.4.4 Japan Monoclonal Antibodies (mAbs) Market by End User
11.3.7.5 South Korea Monoclonal Antibodies (mAbs) Market
11.3.7.5.1 South Korea Monoclonal Antibodies (mAbs) Market by Source
11.3.7.5.2 South Korea Monoclonal Antibodies (mAbs) Market by Production
11.3.7.5.3 South Korea Monoclonal Antibodies (mAbs) Market by Indication
11.3.7.5.4 South Korea Monoclonal Antibodies (mAbs) Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Monoclonal Antibodies (mAbs) Market Overview
11.4.2 Middle East and Africa Monoclonal Antibodies (mAbs) Market Forecasts and Analysis
11.4.3 Middle East and Africa Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Source
11.4.4 Middle East and Africa Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Production
11.4.5 Middle East and Africa Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Indication
11.4.6 Middle East and Africa Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Monoclonal Antibodies (mAbs) Market
11.4.7.1.1 South Africa Monoclonal Antibodies (mAbs) Market by Source
11.4.7.1.2 South Africa Monoclonal Antibodies (mAbs) Market by Production
11.4.7.1.3 South Africa Monoclonal Antibodies (mAbs) Market by Indication
11.4.7.1.4 South Africa Monoclonal Antibodies (mAbs) Market by End User
11.4.7.2 Saudi Arabia Monoclonal Antibodies (mAbs) Market
11.4.7.2.1 Saudi Arabia Monoclonal Antibodies (mAbs) Market by Source
11.4.7.2.2 Saudi Arabia Monoclonal Antibodies (mAbs) Market by Production
11.4.7.2.3 Saudi Arabia Monoclonal Antibodies (mAbs) Market by Indication
11.4.7.2.4 Saudi Arabia Monoclonal Antibodies (mAbs) Market by End User
11.4.7.3 U.A.E Monoclonal Antibodies (mAbs) Market
11.4.7.3.1 U.A.E Monoclonal Antibodies (mAbs) Market by Source
11.4.7.3.2 U.A.E Monoclonal Antibodies (mAbs) Market by Production
11.4.7.3.3 U.A.E Monoclonal Antibodies (mAbs) Market by Indication
11.4.7.3.4 U.A.E Monoclonal Antibodies (mAbs) Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Monoclonal Antibodies (mAbs) Market Overview
11.5.2 South and Central America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis
11.5.3 South and Central America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Source
11.5.4 South and Central America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Production
11.5.5 South and Central America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Indication
11.5.6 South and Central America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By End User
11.5.7 South and Central America Monoclonal Antibodies (mAbs) Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Monoclonal Antibodies (mAbs) Market
11.5.7.1.1 Brazil Monoclonal Antibodies (mAbs) Market by Source
11.5.7.1.2 Brazil Monoclonal Antibodies (mAbs) Market by Production
11.5.7.1.3 Brazil Monoclonal Antibodies (mAbs) Market by Indication
11.5.7.1.4 Brazil Monoclonal Antibodies (mAbs) Market by End User
11.5.7.2 Argentina Monoclonal Antibodies (mAbs) Market
11.5.7.2.1 Argentina Monoclonal Antibodies (mAbs) Market by Source
11.5.7.2.2 Argentina Monoclonal Antibodies (mAbs) Market by Production
11.5.7.2.3 Argentina Monoclonal Antibodies (mAbs) Market by Indication
11.5.7.2.4 Argentina Monoclonal Antibodies (mAbs) Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. MONOCLONAL ANTIBODIES (MABS) MARKET, KEY COMPANY PROFILES
13.1. NOVARTIS AG
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. PFIZER INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. GLAXOSMITHKLINE PLC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. AMGEN, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. DAIICHI SANKYO COMPANY, LIMITED.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ABBOTT
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. ASTRAZENECA
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ELI LILLY AND COMPANY
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. BAYER AG
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BRISTOL-MYERS SQUIBB COMPANY.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis AG
2. Pfizer Inc.
3. GlaxoSmithKline plc.
4. Amgen, Inc.
5. DAIICHI SANKYO COMPANY, LIMITED.
6. Abbott
7. AstraZeneca
8. Eli Lilly and Company
9. Bayer AG
10. Bristol-Myers Squibb Company.